Related Experiment Videos
Ongoing trials involving angiotensin-converting enzyme inhibitors
1University Department of Medicine, City Hospital, Birmingham B18 7QH, UK.
Expert Opinion on Investigational Drugs
|November 20, 2002
Summary
Angiotensin-converting enzyme inhibitors (ACEIs) are crucial for managing cardiovascular diseases, hypertension, and diabetic complications. Ongoing trials continue to explore their efficacy against other drug classes, solidifying their medical importance.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Angiotensin-converting enzyme inhibitors (ACEIs) block the renin-angiotensin-aldosterone system, impacting blood pressure and fluid balance.
- ACEIs are established treatments for hypertension, heart failure, diabetic renal complications, and stroke prevention.
Purpose of the Study:
- To review ongoing clinical trials involving ACEIs.
- To discuss the rationale and expected impact of these trials on current medical understanding.
- To reaffirm the significant role of ACEIs in modern medicine.
Main Methods:
- Review of ongoing clinical trials on ACEIs.
- Analysis of trial rationales and anticipated outcomes.
- Comparison of ACEI efficacy against other drug classes (beta-blockers, ARBs, calcium antagonists).
Main Results:
- Recent trials confirm ACEIs' utility in hypertension, heart failure, diabetic nephropathy, and stroke prevention.
- Ongoing trials investigate ACEIs' comparative efficacy and impact on macro/microvascular complications in diabetes.
Conclusions:
- ACEIs remain a cornerstone therapy in cardiovascular and metabolic disease management.
- Further research is expected to reinforce the indispensable role of ACEIs in clinical practice.
- The ongoing trials will refine the understanding and application of ACEIs across various indications.